Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Crl
  6. /
  7. B & B Pharmaceuticals, Inc.
CRL
•B & B Pharmaceuticals, Inc.

B & B Pharmaceuticals, Inc. – FDA CRL

Record Details

The FDA issued a Complete Response Letter (CRL) to Defender Pharmaceuticals, Inc. for its New Drug Application (NDA 214315) concerning scopolamine nasal gel. The agency determined the application could not be approved due to significant human factors issues, product design deficiencies, and insufficient efficacy data. The primary concern was the device's user interface, which failed to support safe and effective administration. A human factors validation study revealed critical use errors, such as incorrect nozzle wiping or inappropriate dosing (e.g., multiple actuations in one nostril or a single actuation across both), potentially leading to higher-than-intended drug exposure. This was attributed to a conflict with the common mental model for nasal spray usage, where a single dose typically involves administration in both nostrils, contrasting with the intended single actuation in one nostril for this product. To address these deficiencies, Defender Pharmaceuticals must revise the user interface and device design to ensure safe and effective use, providing data to confirm these mitigations. The FDA recommends considering a dose adjustment to align with established user expectations. A redesigned interface and revised human factors validation study protocol must be submitted for agency review. Further requirements include a comprehensive safety update, revisions to prescribing information and carton/container labeling, and resubmission of the proprietary name. The FDA also indicated that the current clinical data are not sufficiently persuasive to demonstrate efficacy for preventing motion-induced nausea, recommending additional clinical trials.

Company
B & B Pharmaceuticals, Inc.
Product type
NDA (New Drug Application)
Office
Center for Drug Evaluation and Research
Person
  • Lisa McNeil
View Company Profile

ID · 379ba443-7948-43f4-bd7b-f72bae024667

Other documents for B & B Pharmaceuticals, Inc.
  • WARNING_LETTER - 2018-10-30October 30, 2018
  • CRL

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore B & B Pharmaceuticals, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.